Table 2.

Studies of Immune Checkpoint Inhibitor PD-1/PD-L1 and CTLA4 from Clinicaltrials.gov (Accessed 15th April 2020)

Clinical Trial Identifier	Agent	Immune Target	Primary Endpoint	Sample Size	Statusa	Phaseb
NCT01693783	Ipilimumab	CTLA-4	response rate	n=44	ongoing	2
NCT01711515	Ipilimumab	CTLA-4	Toxicity	n=34	ongoing	1
NCT01975831	Tremelimumab, Durvalumab (MEDI4736)	CTLA-4, PD-L1	Adverse event	n=106 (include other cancers)	ongoing	1
NCT02257528	Nivolumab	PD-1	response rate	n=26	ongoing	2
NCT02725489	Durvalumab VS Vigil	PD-L1	Adverse event	n=13 (include other cancers)	ongoing	2
NCT02914470	Atezoluzumab	PD-L1	Toxicity	n=12 (include other cancers)	ongoing	1
NCT02921269	Atezoluzumab	PD-L1	Response rate	n=22	ongoing	2
NCT03073525	Atezoluzumab VS Vigil	PD-L1	Adverse event	n=25 (include other cancers)	ongoing	2
NCT03104699	AGEN2034	PD-1	Response rate	n=150	ongoing	1, 2
NCT03635567	Pembrolizumab (MK-3475) VS chemotherapy	PD-1	Overall survival	n=600	ongoing	3

Notes: ^aStatus can be divided into recruit, ongoing, terminated, completed. ^bClinical phase can be divided into 1, 2, 3, 4.